ATAZANAVIR SULFATE; COBICISTAT
| Brand name | EVOTAZ |
|---|---|
| Active ingredient | ATAZANAVIR SULFATE; COBICISTAT |
| Strength | EQ 300MG BASE;150MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10039718 | October 2032 | product |
| 8148374 | September 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.